Vertex Pharmaceuticals Inc (VRTX)

Conclusion

Vertex Pharmaceuticals is a biotechnology company whose medicines for cystic fibrosis form the core of its business, with newer products for sickle cell disease, beta thalassemia and acute pain. At 550.87 USD on 2026-11-09, the shares carry a market capitalisation of 139.67 billion USD.

The verdict is overvalued. The price stands at 35.1 times earnings against a ten-year median of 28.9, and at 43.6 times free cash flow against 39.7. The fair value band runs from 350.16 to 525.24 USD, with a midpoint of 437.70 USD and a margin of safety of -20.5% at the current price. The DCF gives 309.88 USD per share, while the fair value from historical multiples is 565.52 USD. The reverse DCF shows that the price implies growth of 18.8%, against revenue growth of 14.2% a year over five years and free cash flow per share growth of 1.7% a year over the same period.

The case rests on a return on invested capital of 19.4% against a WACC of 8.7%, a net debt to EBITDA of 0.04 and an Altman Z-score of 8.91. The weakest numbers are the margin of safety of -20.5%, the next-year EPS estimate, cut by 8.0% over 90 days, and the Piotroski score of 4 out of 8. Free cash flow per share has also fallen 6.5% a year over three years.

Financial health

Financial strength is green, held up by a net debt to EBITDA of 0.04, interest coverage of 360.8 times, a current ratio of 2.34, a quick ratio of 1.72 and debt to equity of 0.31. The Altman Z-score is 8.91, in the safe zone. The Altman model was designed for manufacturers, so for a biotechnology company this reading is indicative only. Insolvency risk: low, about 0.02% by the estimate of the Ohlson model over one to two years. Balance sheet risk is limited, and the company's debt position is not a constraint on its valuation.

Earnings quality

Earnings quality is green. Free cash flow conversion is 80.5% over the last twelve months and 94.6% over five years, and the accrual ratio is 1.3%. Stock-based compensation equals 5.2% of revenue, and free cash flow after it is 2.53 billion USD. The share count fell at a five-year compound rate of 0.4%, a sign of buybacks. The Piotroski score is 4 of 8 evaluable tests, a moderate reading. The Beneish M-score is not available in the data. Over the last eight quarters the company beat estimates four times and missed three times, with an average surprise of 0.9%. Estimates for the current year fell 4.8% over 90 days, and estimates for next year fell 8.0%, with five upward and two downward revisions in the last 30 days.

Profitability

Profitability is green. The operating margin is 33.9% against a ten-year median of 32.8%, the net margin 30.6% against 31.8%, and the gross margin 85.6% against 87.4%. Margin stability reads 0.69. ROIC is 19.4% against a WACC of 8.7%, and the given ROIC minus WACC value is 10.7 points, so the business creates value. The five-year median ROIC is 52.5%. ROE is 19.0%. The DuPont split for 2025 shows a net margin of 32.7%, an asset turnover of 0.46 and an equity multiplier of 1.40. The return therefore comes mainly from margins rather than from leverage.

Growth

Growth is green. Revenue compounded at 10.6% a year over three years, 14.2% over five and 27.9% over ten. EPS compounded at 6.1% over three years and 8.3% over five. Free cash flow per share fell at 6.5% a year over three years and rose 1.7% over five. Revenue grew in all 10 of 10 comparable years. The next-year EPS growth estimate is 9.9%, which is above the three-year EPS compound rate of 6.1%.

Valuation

Valuation is red, because the valuation test is bad. The price-to-earnings ratio of 35.1 is 21.6% above its ten-year median of 28.9, and the price to free cash flow of 43.6 is 9.9% above its median of 39.7. The EV/EBITDA of 28.2 is 11.4% below its median of 31.8, the price to sales of 10.8 is 2.6% below 11.0, and the price to book of 6.7 is 5.0% below 7.0. The DCF gives 309.88 USD per share at a discount rate of 8.87%, with 14.2% growth in the first stage and 2.5% terminal growth. About 60.9% of that value sits in the terminal value. The fair value band runs from 350.16 to 525.24 USD, with a midpoint of 437.70 USD and a margin of safety of -20.5%. The fair value from historical multiples is 565.52 USD. The fair value is an order-of-magnitude estimate built on fixed assumptions, including a 5% equity risk premium and capped growth, not a price target. The free cash flow yield is 2.3% and the earnings yield 2.9%. The company pays no dividend.

Risks

The main risk is the price itself. At a margin of safety of -20.5%, the shares trade above the fair value midpoint, so the case depends on growth near the 18.8% implied by the price. Revenue has grown 14.2% a year over five years, and free cash flow per share has grown only 1.7%, so that gap is the central concern. Falling next-year estimates, down 8.0% over 90 days, suggest the earnings trajectory may be weaker than the price assumes. A Piotroski score of 4 of 8 and a three-year fall in free cash flow per share of 6.5% add to the caution. Stock-based compensation of 5.2% of revenue also reduces the cash available to shareholders. The Beneish M-score is not available. This analysis has limits: it has no debt maturity schedule and no revenue by segment, so the timing of obligations and the dependence on cystic fibrosis medicines cannot be measured.